Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps Journal Article
| Authors: | Sharma, P.; Wagner, K.; Wolchok, J. D.; Allison, J. P. |
| Article Title: | Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps |
| Abstract: | The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit. © 2011 Macmillan Publishers Limited. All rights reserved. |
| Keywords: | cancer survival; treatment response; unclassified drug; overall survival; drug tolerability; review; sorafenib; bevacizumab; drug efficacy; drug potentiation; unspecified side effect; drug approval; temozolomide; drug megadose; dacarbazine; interleukin 2; ipilimumab; ticilimumab; cancer immunotherapy; melanoma; prostate cancer; drug mechanism; cancer epidemiology; peptide vaccine; provenge; immunosurveillance; maintenance drug dose; gp100 vaccine; prostvac; virus vaccine |
| Journal Title: | Nature Reviews Cancer |
| Volume: | 11 |
| Issue: | 11 |
| ISSN: | 1474-175X |
| Publisher: | Nature Publishing Group |
| Date Published: | 2011-11-01 |
| Start Page: | 805 |
| End Page: | 812 |
| Language: | English |
| DOI: | 10.1038/nrc3153 |
| PROVIDER: | scopus |
| PUBMED: | 22020206 |
| PMCID: | PMC3426440 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 9 December 2011" - "CODEN: NRCAC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work